About Us Clinical Pipeline Science Products Careers PRODUCT INDICATION STATUS REZUROCK™ (belumosudil) (Selective ROCK2 inhibitor) Chronic Graft-Versus-Host Disease (cGVHD) FDA approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systematic therapy Systemic Sclerosis Open-label Phase 2 clinical trial ongoing; initial data expected YE 2021 Phase 2 placebo-controlled clinical trial ongoing KD033 (anti-PD-L1/IL-15 fusion protein) Immuno-oncology Phase 1 clinical trial ongoing Pipeline About cGVHD About Belumosudil About KD033 Clinical Trials About cGVHD Chronic GVHD (cGVHD) is a common complication following hematopoietic cell transplantation (HCT). In cGVHD, transplanted immune cells (graft) attack the patient’s cells (host), leading to inflammation and fibrosis in multiple tissues. Approximately 14,000 patients in the United States are living with cGVHD, and approximately 5,000 new patients are diagnosed with cGVHD per year[1]. [1] Bachier, CR. et al. ASH Annual Meeting 2019, Abstract #2109. Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A U.S. Claims Analysis. cGVHD: INFLAMMATION AND FIBROSIS IN MULTIPLE ORGANS About Belumosudil Belumosudil, is an orally administered, selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). Kadmon’s research has helped define the role of ROCK in the pathogenesis of immune and fibrotic diseases. Kadmon’s research has demonstrated that belumosudil helps to resolve immune dysregulation by down-regulating pro-inflammatory Th17 cells and increasing regulatory T (Treg) cells. ROCK is downstream of major pro-fibrotic mediators and regulates multiple fibrotic processes, including stress fiber formation, myofibroblast activation and pro-fibrotic gene transcription. Belumosudil down-regulated key fibrotic processes in preclinical models, including profibrotic gene transcription, stress fiber formation, myofibroblast activation and collagen deposition. ROCK Inhibition Attenuates Fibrotic Disease Progression Belumosudil in Systemic Sclerosis Systemic Sclerosis (SSc) is a chronic immune disorder characterized by fibrosis of the skin and internal organs. Currently, there are no FDA-approved targeted therapies for SSc, which affects 75,000 to 100,000 people in the United States[2]. Belumosudil, Kadmon’s ROCK2 inhibitor, has demonstrated activity in preclinical sclerodermatous models. Enrollment is ongoing in a randomized, placebo-controlled, Phase 2 clinical trial of belumosudil (KD025-209) in 60 patients with diffuse cutaneous SSc. Enrollment is also ongoing in an open-label, Phase 2 clinical trial of belumosudil (KD025-215) in up to 15 patients with diffuse cutaneous SSc. Initial data from this study are expected by year-end 2021. [2] American College of Rheumatology. “Largest study evaluating survival in systemic sclerosis patients following lung transplantation.” Press release, November 16, 2014. 450 East 29th Street New York, New York 10016 55 Cambridge Parkway, Suite 300E Cambridge, Massachusetts 02142 119 Commonwealth Drive Warrendale, Pennsylvania 15086 Site MapPrivacy PolicyTerms of UseCalifornia Compliance © 2021 Kadmon, a Sanofi Company. All Rights Reserved.